Aura Biosciences is a clinical-stage oncology company developing virus-like drug conjugates (VDCs) that selectively target solid tumors while aiming to spare healthy tissue. Its lead candidate, bel-sar (AU-011), is advanced for early choroidal melanoma, a rare eye cancer with limited drug options that preserve vision. The platform is also being explored in other ocular oncology settings and bladder cancer.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -27 | — |
| Q3 2025 | 0 | — | -26.1 | — |
| Q4 2025 | 0 | — | -25.6 | — |
| Q1 2026 | 0 | — | -33.7 | — |
| Q2 2026 | 0 | — | -45.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Polestar Automotive Holding UK PLC (PSNYW), Grid Dynamics Holdings, Inc. (GDYN), Prime Medicine, Inc. (PRME), AGNT, Inc (AGNT), Attovia Therapeutics, Inc. (ATTO), Candel Therapeutics, Inc. (CADL)